FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
SEATTLE, Jan. 27, 2016 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company’s management is scheduled to present at the Leerink Partners 5th Annual Global Healthcare Conference in New York City.
Brad Gray, President and Chief Executive Officer, is scheduled to present on Wednesday, February 10, 2016 at 1:50pm ET. Interested parties can access the live webcast from the investor section of the company’s website at www.nanostring.com. The webcast replay will be available one hour after the conclusion of the live presentation and archived for 90 days.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
Investor Contact: Leigh Salvo of Westwicke Partners For NanoString Technologies [email protected] 415-513-1281
